Finance

Lists
RLMD:NASDAQ
Relmada Therapeutics Inc
US$ ३.२५
-०.९१%
(-०.०३०) 1D
US$ ३.२५
०.००% (०.००)
After hours
Closed: अक्टोबर ७, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RLMD...
Open
US$ ३.२६
High
US$ ३.३६
Low
US$ ३.२४
Mkt. cap
३४.६७ करोड
Avg. vol.
१२.०९ लाख
Volume
१४.९७ लाख
52-wk high
US$ ८.००
52-wk low
US$ १.८०
EPS
-US$ ०.९६
Beta
०.५१
Shares outstanding
१०.६७ करोड
No. of employees
१७
Open
US$ ३.२६
High
US$ ३.३६
Low
US$ ३.२४
Mkt. cap
३४.६७ करोड
Avg. vol.
१२.०९ लाख
Volume
१४.९७ लाख
52-wk high
US$ ८.००
52-wk low
US$ १.८०
EPS
-US$ ०.९६
Beta
०.५१
Shares outstanding
१०.६७ करोड
No. of employees
१७
News stories
From web sources and news partners
marketscreener.com
marketscreener.com
·
१८ मिनेट पहिले
Freshworks Inc.(NasdaqGS: FRSH) added to S&P Composite 1500
Northeast Mississippi Daily Journal
Northeast Mississippi Daily Journal
·
१८ मिनेट पहिले
Wall Street retreats from its record as stocks fall worldwide
Simply Wall Street
Simply Wall Street
·
१ घण्टा पहिले
Powell Industries (POWL) Could Be 41% Undervalued As LNG And Data Center Demand Builds
CNBC
CNBC
·
२ घण्टा पहिले
Anthropic will be 'most ridiculous IPO' of year, analyst says
About Relmada Therapeutics Inc
CEO-
Employees१७
Founded२००४
HeadquartersCoral Gables, फ्लोरिडा, संयुक्त राज्य अमेरिका
Sector-
Websiterelmada.com
Analyst ratings
Based on 2 analysts giving stock ratings to RLMD in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RLMD in the last 3 months.
Highest
Current US$ ३.२५
US$ १२.०० (+२६९.२३%)
Average
US$ १२.०० (+२६९.२३%)
Lowest
US$ १२.०० (+२६९.२३%)
Analyst
Recommendation
Action
Price target
Projected
Date
Uy Ear
Mizuho Securities
Buy
Reiterated
US$ १९.००
+४८४.६%
08/11/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
US$ १२.००
+२६९.२%
08/10/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
US$ १२.००
+२६९.२%
08/07/2026
Christopher Liu
Lucid Capital
Buy
Initiated
US$ १४.००
+३३०.८%
03/02/2026
Last report
२०२२ नोभेम्बर १०
Fiscal period
Q3 2022
EPS / Est. (USD)
-US$ १.२६ / -US$ १.४७
+१४.२२%beat
Revenue / Est. (USD)
- / ०.००
Fiscal Q3 2022 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
४०.३६ लाख
५१.७२ लाख
८०.८८ लाख
८३.९४ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
६२.९१ लाख
१.२३ करोड
१.१४ करोड
६६.१७ लाख
Operating expense
१.०३ करोड
१.७४ करोड
१.९५ करोड
१.५० करोड
Total operating expenses
१.०३ करोड
१.७४ करोड
१.९५ करोड
१.५० करोड
Operating income
-१.०३ करोड
-१.७४ करोड
-१.९५ करोड
-१.५० करोड
Other non operating income
-
-
-
-
EBT including unusual items
-१.०१ करोड
-१.९९ करोड
-१.९१ करोड
-१.२९ करोड
EBT excluding unusual items
-१.०१ करोड
-१.७० करोड
-१.८५ करोड
-१.२७ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.०१ करोड
-१.९९ करोड
-१.९१ करोड
-१.२९ करोड
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
२.४७ लाख
३.८७ लाख
९.६० लाख
२३.०१ लाख
Interest expense
-
-
-
-
Net interest expenses
२.४७ लाख
३.८७ लाख
९.६० लाख
२३.०१ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू